| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-228 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Radium-226 | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Increased risk of cancer |